Search for other works by this author on: ...
Adding the PD-1 inhibitor pembrolizumab to chemoradiotherapy for high-risk, locally advanced cervical cancer significantly improves patients’ overall survival compared to treatment with CRT alone.
Search for other works by this author on: ...
University of Nebraska Medical Center, Omaha, NE, ...
This open access article is distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) license. This work is licensed under a Creative Commons ...
Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain.
Copyright held by the owner/author(s).
UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania.
The FDA approved the PD1 inhibitor atezolizumab plus hyaluronidase (Tecentriq Hybreza; Genentech), which helps the drug move into tissues, as a subcutaneous injection for the same adult indications as ...
Two HER2-targeted tyrosine kinase inhibitors, BAY 29270078 and zongertinib, each showed robust efficacy and safety in early phase. Patients experienced significant tumor shrinkage rates, and the ...
Search for other works by this author on: ...
Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback